Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001239241-19-000001
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-04 17:33:26
Reporting Period:
2019-10-03
Accepted Time:
2019-10-04 17:33:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434418 Constellation Pharmaceuticals Inc CNST () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1239241 B Anthony Evnin C/o Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-10-03 2,823,529 $8.50 5,342,765 No 4 P Indirect By Funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Funds
Footnotes
  1. Consists of an aggregate of 550,770 shares of Common Stock purchased by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 223,184 shares of Common Stock purchased by VHCP Co-Investment Holdings II, LLC ("Co-Invest II"), 1,863,351 shares of Common Stock purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 186,224 shares of Common Stock purchased by VHCP Co-Investment Holdings III, LLC ("Co-Invest III") (collectively, the "VHCP Funds") pursuant to that certain Securities Purchase Agreement, dated October 1, 2019, by and among the Issuer and the Investors identified on Exhibit A thereto.
  2. Consists of an aggregate of 1,557,276 shares of Common Stock held by Venrock Associates V, L.P. ("VA5"), 132,026 shares of Common Stock held by Venrock Partners V, L.P. ("VP5"), 36,590 shares of Common Stock held by Venrock Entrepreneurs Fund V, L.P. ("VEF5") (collectively, the "V5 Funds"), 1,923,958 shares of Common Stock held by VHCP III, 192,284 shares of Common Stock held by Co-Invest III, 1,067,801 shares of Common Stock held by VHCP II and 432,830 shares of Common Stock held by Co-Invest II.
  3. Venrock Management V, LLC ("VM5"), Venrock Partners Management V, LLC ("VPM5"), and VEF Management V, LLC ("VEFM5") are the sole general partners of VA5, VP5 and VEF5, respectively, and may be deemed to own the shares held by the V5 Funds. Dr. Evnin is one of more than three members of VM5, VPM5 and VEFM5. VHCP Management III, LLC ("VHCPM III") is the sole general partner and the sole manager of VHCP III and Co-Invest III, respectively, and may be deemed to own the shares held by VHCP III and Co-Invest III. VHCP Management II, LLC ("VHCPM II") is the sole general partner and the sole manager of VHCP II and Co-Invest II, respectively, and may be deemed to own the shares held by VHCP II and Co-Invest II. Bong Koh and Nimish Shah are the sole managers of VHCPM III and VHCPM II. Dr. Evnin disclaims beneficial ownership over all shares held by the V5 Funds and the VHCP Funds except to the extent of his indirect proportionate pecuniary interest therein.